Loading company…
Mabgeek develops antibody drugs for respiratory, skin and kidney diseases.
Established in 2016, Mabgeek researches antibody drugs for respiratory diseases, dermatitis and nephropathy. Its lead product, MG-K10, is a monoclonal antibody targeting IL-4Ra. The company raised CNY 260 million in Pre-IPO funding in August 2025, led by China Medical System Holdings Limited, with participation from GF Qianhe, XJSCI and Zhongshan Venture Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in